

S 3220

A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.

Congress: 118 (2023–2025, Ended)

Chamber: Senate

Policy Area: Health

Introduced: Nov 2, 2023

Current Status: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest Action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Nov 2, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/senate-bill/3220>

Sponsor

Name: Sen. Kelly, Mark [D-AZ]

Party: Democratic • **State:** AZ • **Chamber:** Senate

Cosponsors (4 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Sinema, Kyrsten [I-AZ]	I · AZ		Nov 2, 2023
Sen. Mullin, Markwayne [R-OK]	R · OK		Dec 6, 2023
Sen. Hickenlooper, John W. [D-CO]	D · CO		Jan 31, 2024
Sen. Merkley, Jeff [D-OR]	D · OR		Mar 6, 2024

Committee Activity

Committee	Chamber	Activity	Date
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Nov 2, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
118 S 3464	Related bill	Dec 12, 2023: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
118 HR 6227	Related bill	Nov 10, 2023: Referred to the Subcommittee on Health.

Summary (as of Nov 2, 2023)

This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

Actions Timeline

- **Nov 2, 2023:** Introduced in Senate
- **Nov 2, 2023:** Read twice and referred to the Committee on Health, Education, Labor, and Pensions.